Results 1 to 10 of about 1,787,106 (336)

The Drug Reaction Problem

open access: bronzeThe American Journal of Digestive Diseases, 1967
Henry J. Tumen   +4 more
openalex   +6 more sources

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam

open access: yesFrontiers in Pharmacology, 2022
Background: The World health organization (WHO) recently recommended standardized all-oral shorter regimens for rifampicin resistant Tuberculosis (RR-TB).
Thi Mai Phuong Nguyen   +8 more
doaj   +1 more source

Novel Therapeutic Targets in Liver Fibrosis

open access: yesFrontiers in Molecular Biosciences, 2021
Liver fibrosis is end-stage liver disease that can be rescued. If irritation continues due to viral infection, schistosomiasis and alcoholism, liver fibrosis can progress to liver cirrhosis and even cancer.
Jinhang Zhang   +4 more
doaj   +1 more source

Study of prescribing errors of two different prescription systems: pre-printed prescription from historical medication and hand-written prescription [PDF]

open access: yesPharmaceutical Sciences Asia, 2022
A retrospective observational study of 1,160 prescriptions with prescribing errors from a large academic hospital in Thailand from 2014 to 2017. The aims of this study are to explore the proportion of prescribing error from pre-printed prescriptions and ...
Nisa Sae-lim, Ploylarp Lertvipapath
doaj   +1 more source

Inhibition of 5-Lipoxygenase in Hepatic Stellate Cells Alleviates Liver Fibrosis

open access: yesFrontiers in Pharmacology, 2021
Background and Purpose: Activation of hepatic stellate cells (HSC) is a central driver of liver fibrosis. 5-lipoxygenase (5-LO) is the key enzyme that catalyzes arachidonic acid into leukotrienes.
Shiyun Pu   +28 more
doaj   +1 more source

Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease

open access: yesPharmaceutics, 2021
Background: Ceftazidime and imipenem have been increasingly used to treat Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) due to their extended-spectrum covering Pseudomonas aeruginosa.
Thu-Minh Nguyen   +11 more
doaj   +1 more source

Apigenin reduces the suppressive effect of exosomes derived from irritable bowel syndrome patients on the autophagy of human colon epithelial cells by promoting ATG14

open access: yesWorld Journal of Surgical Oncology, 2023
Background Inflammatory bowel disease (IBS) is a chronic disorder of the gastrointestinal tract. Exosomes have been involved in various pathological processes including IBS. Apigenin has been reported to suppress inflammatory bowel disease (IBS). However,
Rui Fu   +4 more
doaj   +1 more source

Drug-Related Deaths in China: An Analysis of a Spontaneous Reporting System

open access: yesFrontiers in Pharmacology, 2022
Background: Adverse drug reactions with an outcome of death represent the most serious consequences and are inherently important for pharmacovigilance.
Haona Li   +3 more
doaj   +1 more source

Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics

open access: yesFrontiers in Pharmacology, 2022
SCARs are rare and life-threatening hypersensitivity reactions. In general, the increased duration of hospital stays and the associated cost burden are common issues, and in the worst-case scenario, they can result in mortality.
Therdpong Tempark   +13 more
doaj   +1 more source

Differential Diagnosis of Fever of Unknown Origin in Drug Reaction with Eosinophilia and Systemic Symptom (DRESS)

open access: yesInternational Journal of Integrated Health Sciences, 2022
Objective: To describe an unusual case of drug reaction with eosinophilia and systemic symptoms presenting as fever of unknown origin (FUO) and the diagnostic hurdles that come with the presence of differential diagnosis of FUO, which is tuberculous ...
Kevin Fachri Muhammad   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy